Our trial provides proof of concept that cytokine-armored CAR T-cell treatment is feasible and may enhance antitumor activity without additional toxic effects,” researchers reported.

UK-based Leucid Bio has dosed the first subject in the multi-centre Phase I AERIAL trial of autologous lateral chimeric ...

Second of 2 parts featuring an interview with Stephen Strickland, MD, MSCI,director, Leukemia Research for Sarah Cannon ...

Study in mice found transient microglial depletion, or chemokine receptor blockade, resolved immunotherapy-related cognitive impairment.

Cancer treatment with a cell-based immunotherapy causes mild cognitive impairment, a Stanford Medicine team found. They also identified compounds that could treat it.

After treatment with CAR-T cells - immune cells engineered to attack cancer - patients sometimes tell their doctors they feel like they have "brain fog," or forgetfulness and difficulty concentrating.

Initiation of AERIAL trial accelerated by successful first close of Series A1 financing  LEU011 is first CAR-T candidate for the treatment of solid tumours to be manufactured ...

Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionised cancer treatment, especially for aggressive and ...

Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, seem to align with recent bad news for this ...

Once prostate cancer no longer responds to hormonal therapy, the cancer is called castration-resistant. Find out which ...